| Next 10 |
Ad
MGTX News and Press MeiraGTx Holdings plc
News | MeiraGTx Holdings plc (NASDAQ:MGTX)
-
2025-03-13 08:38:23 ET More on MeiraGTx MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value MeiraGTx rises after publication of positive data from gene therapy trial for eye disorder MeiraGTx receives rare pediatric disease designation from FDA ...
-
2025-03-13 08:08:57 ET More on MeiraGTx MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value MeiraGTx rises after publication of positive data from gene therapy trial for eye disorder MeiraGTx receives rare pediatric disease designation from FDA ...
-
Team Inc. (TISI) is expected to report for quarter end 2024-12-31 Chesswood Group Limited (CHWWQ) is expected to report for Q4 2024 J. W. Mays Inc. (MAYS) is expected to report for Q2 2025 Allakos Inc. (ALLK) is expected to report $-0.17 for Q4 2024 Aurora Mobile Limited (JG) is e...
-
2025-02-23 03:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
2025-02-21 14:05:10 ET More on MeiraGTx MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value MeiraGTx Holdings: Behind The Recent Rally MeiraGTx receives rare pediatric disease designation from FDA for its eye disease treatment Seeking Al...
-
2025-01-22 16:09:06 ET Summary MeiraGTx Holdings plc is advancing AAV-AIPL1 for AIPL1-associated Leber congenital amaurosis 4, with a near-term BLA filing in the UK under Exceptional Circumstance possible. Bota-vec, developed with Janssen, could see a BLA filing for X-linked Retin...
-
2025-01-22 09:18:26 ET More on MeiraGTx MeiraGTx Holdings: Behind The Recent Rally MeiraGTx GAAP EPS of -$0.55 misses by $0.02, revenue of $10.91M beats by $9.28M Seeking Alpha’s Quant Rating on MeiraGTx Historical earnings data for MeiraGTx Fi...
-
- RMAT designation recognizes the preliminary clinical evidence of the potential benefit of AAV2-hAQP1 as a one-time treatment for this debilitating condition - RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy designations, allows frequent regu...
-
2024-12-03 14:18:54 ET Summary MeiraGTx Holdings plc has rallied over 40% following promising Parkinson’s disease data, with significant potential in its Riboswitch platform for gene expression control. The company’s diverse pipeline includes gene therapies for saliv...
-
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors PR Newswire ROCKVILLE, Md. and SUZHOU, China , Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged ...
Stock Information
Get MGTX Alerts
News, Short Squeeze, Breakout and More Instantly...
MeiraGTx Holdings plc Company Name:
MGTX Stock Symbol:
NASDAQ Market:
1.44% G/L:
$7.56 Last:
849,485 Volume:
$7.54 Open:
$7.56 Close:
MeiraGTx Holdings plc Website:
Ad
-
Team Inc. (TISI) is expected to report for quarter end 2024-12-31 Chesswood Group Limited (CHWWQ) is expected to report for Q4 2024 J. W. Mays Inc. (MAYS) is expected to report for Q2 2025 Allakos Inc. (ALLK) is expected to report $-0.17 for Q4 2024 Aurora Mobile Limited (JG) is e...
-
2025-02-23 03:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
- RMAT designation recognizes the preliminary clinical evidence of the potential benefit of AAV2-hAQP1 as a one-time treatment for this debilitating condition - RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy designations, allows frequent regu...